1018569-94-2

Basic information

• Product Name: N-methyl-4-(piperazin-1-yl)benzamide
• Synonyms: N-methyl-4-(piperazin-1-yl)benzamide
• CAS NO: 1018569-94-2
• Molecular Weight: 219.286
• Mol File: 1018569-94-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-methyl-4-(piperazin-1-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-4-(piperazin-1-yl)benzamide(1018569-94-2)
• EPA Substance Registry System: N-methyl-4-(piperazin-1-yl)benzamide(1018569-94-2)

Safety Data

• Hazardous Substances Data: 1018569-94-2(Hazardous Substances Data)

Upstream product

• 456-22-4 4-Fluorobenzoic acid 
• 110-85-0 piperazine 
• 701-49-5 4-fluoro-N-methylbenzamide 

Downstream Products

• 1236117-05-7 (S)-N-methyl-4-(4-((6-oxo-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-3-yl)methyl)piperazin-1-yl)benzamide 
• 1246083-26-0 4-(4-((8-methoxy-2-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)methyl)piperazin-1-yl)-N-methylbenzamide 
• 1246083-87-3 N-methyl-4-(4-((2-methyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)methyl)piperazin-1-yl)benzamide 
• 1263407-42-6 N-methyl-4-(4-((6-oxo-5,6-dihydropyrido[2,3-e]pyrrolo[1,2-c]pyrimidin-3-yl)methyl)piperazin-1-yl)benzamide 

Relevant articles and documents

Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose) polymerase inhibitors

Structure based drug design of a series of novel 1,4-benzoxazin-3-one derived PARP-1 inhibitors are described. The synthesis, enzymatic & cellular activities and pharmacodynamic effects are described. Optimized analogs demonstrated inhibition of poly-ADP-ribosylation in SW620 tumor bearing nude mice through 24 h following a single dose.

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors

Disclosed are compounds of the following formula: in which R1, R2, R3, R4, R5, R6, R7, X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.